Should be interestingI assume since Jazz lost their lawsuit with Avadel based on '963 patent discrepancies, the 15 or so corporations that GW is now suing for Epidiolex infringement, will stroll down that same path of orange book patent delisting. Will United States Patent No. 11,633,369 (“the ’369 patent”), owned by GW meet the same fate as the '963 patent?
Stay tuned as it could be a billion dollar question!
"The district court found that, as a matter of claim construction, the ’963 patent claimed a system—not a method of use—and ordered Jazz to delist the ’963 patent from the Orange Book. The Jazz appealed that decision and the Federal Circuit affirmed." https://www.jdsupra.com/legalnews/jazz-pharms-inc-v-avadel-cns-pharms-1859324/